We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

139 hedge funds and large institutions have $326M invested in iShares US Pharmaceuticals ETF in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 39 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.93% more ownership

Funds ownership: 55.86% → 58.79% (+2.9%)

3% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 39

6% less capital invested

Capital invested by funds: $345M → $326M (-$19.1M)

7% less funds holding

Funds holding: 149 → 139 (-10)

42% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 24

Holders
139
Holders Change
-10
Holders Change %
-6.71%
% of All Funds
1.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
40
Reduced
39
Closed
24
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$13M
2
JP Morgan Chase
JP Morgan Chase
New York
+$6.4M
3
Goldman Sachs
Goldman Sachs
New York
+$2.19M
4
GC
Grimes & Company
Massachusetts
+$1.46M
5
Ameriprise
Ameriprise
Minnesota
+$1.28M

Top Sellers

Rank Fund Capital Flow
1
Fisher Asset Management
Fisher Asset Management
Washington
-$10.8M
2
ClearBridge Investments
ClearBridge Investments
New York
-$1.9M
3
Morgan Stanley
Morgan Stanley
New York
-$1.88M
4
Wells Fargo
Wells Fargo
California
-$1.34M
5
Bank of America
Bank of America
North Carolina
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
WAP
51
Wealthcare Advisory Partners
Pennsylvania
$321K +$13.1K +201 +4%
CAPTRUST Financial Advisors
52
CAPTRUST Financial Advisors
North Carolina
$315K -$17.8K -274 -5%
KAS
53
Kestra Advisory Services
Texas
$314K -$30.9K -474 -9%
RMAM
54
Raab & Moskowitz Asset Management
New Jersey
$308K -$7.16K -110 -2%
MML Investors Services
55
MML Investors Services
Massachusetts
$302K +$86.4K +1,328 +40%
FDCDDQ
56
Federation des caisses Desjardins du Quebec
Quebec, Canada
$287K +$13K +200 +5%
PAG
57
Private Advisor Group
New Jersey
$282K -$22.4K -344 -7%
ASN
58
Advisory Services Network
Georgia
$275K -$7.68K -118 -3%
NFC
59
Northeast Financial Consultants
Connecticut
$271K – – –
SWM
60
Spire Wealth Management
Virginia
$266K -$33.2K -510 -11%
Wealth Enhancement Advisory Services
61
Wealth Enhancement Advisory Services
Minnesota
$264K +$258K +3,967 New
WA
62
Waverly Advisors
Alabama
$256K – – –
Mercer Global Advisors
63
Mercer Global Advisors
Colorado
$253K -$7.88K -121 -3%
SS
64
Sunbelt Securities
Texas
$243K +$241K +3,702 New
MGIA
65
Matthew Goff Investment Advisor
Texas
$237K – – –
AF
66
Apexium Financial
Texas
$228K +$456 +7 +0.2%
AFC
67
AFT Forsyth & Company
Florida
$225K +$651 +10 +0.3%
SFA
68
Sequoia Financial Advisors
Ohio
$225K – – –
PCMF
69
Private Capital Management (Florida)
Florida
$224K – – –
CSP
70
Cary Street Partners
Virginia
$218K – – –
ESB
71
Essex Savings Bank
Connecticut
$216K – – –
VFG
72
V2 Financial group
Illinois
$216K – – –
Focus Partners Wealth
73
Focus Partners Wealth
Massachusetts
$204K +$1.17K +18 +0.6%
KWA
74
Kingswood Wealth Advisors
California
$203K +$202K +3,100 New
SFI
75
SPC Financial Inc
Maryland
$203K – – –
1 2
3
4 5

IHE Hedge Fund Activity: Q2 2025 in Review

139 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2025, worth a combined $326M — down 5.6% from $345M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of IHE and 14 opened new positions — a net loss of 10 holders — while 39 trimmed existing stakes and 40 added.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $13M. The largest seller was Fisher Asset Management, cutting an estimated $10.8M.

  • 139 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2025, down from 149 in Q1 2025.
  • Funds reported $326M of iShares US Pharmaceuticals ETF stock for Q2 2025, down 5.6% quarter-over-quarter.
  • 14 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2025 and 24 closed out, a net change of -10 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2025 was BNP Paribas Financial Markets, an estimated $13M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2025 was Fisher Asset Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q2 2025.